• Vivesto receives positive new Cantrixil preclinical results in AML

    November 4, 2025

    Read more

  • Nomination Committee appointed for the Annual General Meeting 2026 in Vivesto

    November 7, 2025

    Read more

  • Annual report 2024

    April 8, 2025
    (Only distributed in Swedish)

    Read the report

  • Vivesto reports positive interim results for Paccal Vet pilot study in dogs

    November 7, 2025

    Read more

Vivesto licenses Apealea to China’s Zhida Pharmaceutical

March 18, 2025

Read more

CEO corner

Learn more (in Swedish)

Press releases

All press releases

Interim Report Q2 2025 (in Swedish)

Vivesto published its Q2 report for 2025 on August 12, 2025, at 08.00 am CEST.

Calendar

All events

The Share

Follow the share
Visit our Investor section

Annual Report 2024

Read the report